SCHEMBL104743

SCHEMBL104743

COCCCCNC(C)C

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
ADRB2 P07550 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
HTR1B P28222 1/20 0.37
NR2E1 Q9Y466 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
GAA P10253 1/20 0.35
HRH4 Q9H3N8 2/20 0.35
HRH3 Q9Y5N1 2/20 0.35
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16692609 0.98 ALDH1A1 (0.37) ALDH1A1KDM4EADRB2SLC6A2SLC6A4
SCHEMBL8262524 0.92
SCHEMBL25075482 0.84 MAPK1 (0.39) ALDH1A1KDM4EADRB2HTR1BNR2E1
SCHEMBL28765742 0.82 KDM4E (0.39) ALDH1A1KDM4EADRB2HTR1BNR2E1
SCHEMBL178420 0.81
SCHEMBL2600364 0.81 HRH4 (0.43) ALDH1A1KDM4EADRB2HTR1BNR2E1
SCHEMBL5115915 0.79 SLC6A4 (0.34) ALDH1A1KDM4ESLC6A2SLC6A4SLC6A3
SCHEMBL15182519 0.79 ADRB2 (0.39) ALDH1A1KDM4EADRB2HTR1BNR2E1
Hydrochloric Acid SCHEMBL9731497 0.79
SCHEMBL24477365 0.78 ALDH1A1 (0.44) ALDH1A1KDM4EADRB2HTR1BNR2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10040771-B2 Method for preparing prostacyclin receptor agonist 4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]-1-butanol Seasons Biotechnology (Taizhou) Co., Ltd. (CN) 2018-08-07 US disclosed
US-20180029998-A1 METHOD FOR PREPARING PROSTACYCLIN RECEPTOR AGONIST Seasons Biotechnology (Taizhou) Co., Ltd. (CN) 2018-02-01 US disclosed
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION ONCOTHERAPY SCIENCE, INC. (JP) 2012-03-08 US disclosed
EP-2103619-A1 IMIDAZOTHIAZOLE DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10040771-B2 Method for preparing prostacyclin receptor agonist 4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]-1-butanol PTGIR, TBXA2R, PTGIS ALDH1A1 1155/4885KDM4E 3409/4885ADRB2 13/4885
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION NR0B1, GRK7, NR5A2 ALDH1A1 3128/4885KDM4E 2800/4885ADRB2 223/4885
US-20180029998-A1 METHOD FOR PREPARING PROSTACYCLIN RECEPTOR AGONIST PTGIR, TBXA2R, PTGIS ALDH1A1 2211/4885KDM4E 3408/4885ADRB2 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.